crac channel

Tanshinone IIA sulfonate sodium (Tanshinone IIA sodium sulfonate) is a water-soluble derivative of tanshinone IIA extracted from Savia miltiorrhiza; a potent negative allosteric modulator of the human purinergic receptor P2X7. Tanshinone IIA sulfonate sodium (12.5 μM) inhibits hypoxia-induced PKG and PPAR-γ downregulation in PASMCs and distal pulmonary arteries of rats.

CRAC intermediate 1 is a key intermediate used in the synthesis of the CRAC ion channel series of compounds, details from patent WO 2010122089.

Synta66 is a store-operated calcium entry channel Orai inhibitor, and used for the research of neurological disease.

GSK-7975A is a potent, orally available inhibitor of the Calcium Release-Activated Calcium (CRAC) channel.

SKF-96365 hydrochloride (SKF96365) , a SOCE inhibitor, exhibits potent anti-neoplastic activity by inducing cell-cycle arrest and apoptosis in colorectal Y cells. SKF-96365 hydrochloride can induce cytoprotective autophagy to delay apoptosis by preventing the release of cytochrome c (cyt c) from the mitochondria into the cytoplasm. Mechanistically, SKF-96365 hydrochloride treatment inhibited the calcium/calmodulin-dependent protein kinase IIγ (CaMKIIγ)/AKT signaling cascade in vitro and in vivo. Overexpression of CaMKIIγ or AKT abolished the effects of SKF-96365 on Y cells, suggesting a critical role of the CaMKIIγ/AKT signaling pathway in SFK-96365-induced biological effects. SKF-96365 hydrochloride inhibited hERG current in a concentration-dependent manner.

5J-4 is a potent a blocker of calcium release-activated calcium (CRAC) channel and store-operated calcium entry (SOCE). 5J-4 reduces the production of IL-17 and decreases the expression of RORα and RORγt.

YM-58483 (BTP2) is a specific and effective inhibitor of CRAC channels and subsequent Ca2+ signals.

RO2959 Hydrochloride (RO2959 HCl) is a potent and selective inhibitor of CRAC channel(IC50: 402 nM). It is also a potent inhibitor of human IL-2.

Zegocractin (CM-4620) is an inhibitor of calcium-release activated calcium (CRAC) channels.

CRAC intermediate 2 is used as an intermediate compound in the synthesis of CRAC inhibitors.

Pyr6 (N-[4-[3,5-Bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-fluoro-4-pyridinecarboxamide) is a selective TRPC3 inhibitor with IC50 of 0.49 uM(Ca2+ influx inhibition in thapsigargin depleted native RBL-2H3 cells).Pyr6 is an inhibitor of Ca2+ entry, which displays higher potency to inhibit Ca2+ entry mediated by CRAC channel than by TRPC3.

GSK-5503A is a novel channel blocker of CRAC.

piCRAC-1 is a powerful inhibitor of the photoinducible Ca2+ release-activated Ca2+ (CRAC) channel. It effectively alleviates thrombocytopenia and hemorrhage [1].

AMG-1 is a specific CRAC channel inhibitor. AMG-1 blocks the function of effector T cells, but not regulatory T cells in vitro and it attenuates the progression and severity of EAE in vivo.

Anti-Orai1 Antibody is a humanized monoclonal antibody targeting Calcium Release-Activated Calcium Modulator 1 (Orai1/CRACM1). Orai1 forms the pore subunit of the Calcium Release-Activated Calcium (CRAC) channel on the plasma membrane, mediating Store-Operated Calcium Entry (SOCE). In T lymphocytes, antigen receptor stimulation depletes endoplasmic reticulum calcium stores, triggering STIM1 to activate Orai1 and induce sustained calcium influx, a critical step for NFAT activation and cytokine (e.g., IL-2) production. This antibody specifically binds to the extracellular loops of Orai1, blocking the channel pore or disrupting STIM1-Orai1 coupling, thereby inhibiting SOCE and downstream immune responses. It is widely used in research on autoimmune diseases, inflammation, and calcium signaling-dependent tumors.